{"id":69598,"date":"2026-07-08T14:20:08","date_gmt":"2026-07-08T06:20:08","guid":{"rendered":"https:\/\/flcube.com\/?p=69598"},"modified":"2026-07-08T14:20:09","modified_gmt":"2026-07-08T06:20:09","slug":"insilico-medicine-launches-phase-3-trial-for-ai-discovered-rentosertib-in-idiopathic-pulmonary-fibrosis","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=69598","title":{"rendered":"Insilico Medicine Launches Phase 3 Trial for AI-Discovered Rentosertib in Idiopathic Pulmonary Fibrosis"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Insilico Medicine<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/3696:HKG\">HKG: 3696<\/a>) announced the initiation of a <strong>Phase 3 clinical trial<\/strong> (CTR20262475, NCT07687459) for <strong>Rentosertib (ISM001-055)<\/strong>, a potential <strong>first-in-class small-molecule inhibitor<\/strong> for <strong>idiopathic pulmonary fibrosis (IPF)<\/strong> discovered using the company&#8217;s proprietary <strong>generative AI platform, Pharma.AI<\/strong>. The molecule has received <strong>Orphan Drug Designation from the U.S. FDA<\/strong> and <strong>Breakthrough Therapy Designation from China&#8217;s CDE<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-clinical-trial-design-amp-regulatory-status\" class=\"wp-block-heading\">Clinical Trial Design &amp; Regulatory Status<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Insilico Medicine (HKG: 3696)<\/td><\/tr><tr><td><strong>Drug Candidate<\/strong><\/td><td>Rentosertib (ISM001-055)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Idiopathic pulmonary fibrosis (IPF)<\/td><\/tr><tr><td><strong>Trial Phase<\/strong><\/td><td>Phase 3<\/td><\/tr><tr><td><strong>Trial Identifiers<\/strong><\/td><td>CTR20262475 (China), NCT07687459 (US)<\/td><\/tr><tr><td><strong>Design<\/strong><\/td><td>Randomized, double-blind, placebo-controlled<\/td><\/tr><tr><td><strong>Duration<\/strong><\/td><td>52 weeks<\/td><\/tr><tr><td><strong>Enrollment<\/strong><\/td><td>~320 subjects across 47 research centers (China)<\/td><\/tr><tr><td><strong>Dosing<\/strong><\/td><td>Once-daily oral administration<\/td><\/tr><tr><td><strong>Regulatory Designations<\/strong><\/td><td>FDA Orphan Drug Designation<br>CDE Breakthrough Therapy Designation<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-primary-amp-secondary-endpoints\" class=\"wp-block-heading\">Primary &amp; Secondary Endpoints<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Primary Endpoint<\/strong>: Annual rate of decline in <strong>forced vital capacity (FVC)<\/strong> over 52 weeks<\/li>\n\n\n\n<li><strong>Secondary Endpoints<\/strong>:<\/li>\n\n\n\n<li>Time to first disease progression<\/li>\n\n\n\n<li>Changes in <strong>diffusing capacity of the lungs for carbon monoxide (DLCO)<\/strong><\/li>\n\n\n\n<li>Quality-of-life measures based on validated questionnaire assessments<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The trial&#8217;s robust endpoint selection aligns with regulatory requirements for IPF drug approval and addresses both physiological and patient-reported outcomes critical to demonstrating clinical benefit.<\/p>\n\n\n\n<h2 id=\"h-ai-driven-discovery-amp-development-innovation\" class=\"wp-block-heading\">AI-Driven Discovery &amp; Development Innovation<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Pharma.AI Platform<\/strong>: Rentosertib represents one of the first clinical-stage molecules <strong>entirely discovered and optimized<\/strong> using Insilico&#8217;s <strong>generative AI platform<\/strong>, which integrates target identification, molecular generation, and preclinical validation in an end-to-end computational workflow.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Development Timeline Acceleration<\/strong>: The AI-driven approach enabled Insilico to progress from target identification to IND submission in approximately <strong>18 months<\/strong>, significantly faster than traditional drug discovery timelines of 4-6 years.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>First-in-Class Potential<\/strong>: As a novel mechanism targeting pathways distinct from current IPF therapies (pirfenidone and nintedanib), Rentosertib offers potential for improved efficacy, tolerability, or combination therapy opportunities.<\/p>\n\n\n\n<h2 id=\"h-market-opportunity-amp-competitive-landscape\" class=\"wp-block-heading\">Market Opportunity &amp; Competitive Landscape<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Unmet Medical Need<\/strong>: IPF affects approximately <strong>1 million patients globally<\/strong> with a median survival of 3-5 years post-diagnosis, creating significant demand for more effective therapies.<\/li>\n\n\n\n<li><strong>Market Size<\/strong>: The global IPF therapeutics market is projected to reach <strong>$4.5 billion by 2030<\/strong>, with limited treatment options driving premium pricing for innovative mechanisms.<\/li>\n\n\n\n<li><strong>Regulatory Advantages<\/strong>: Dual designation as <strong>Orphan Drug<\/strong> (FDA) and <strong>Breakthrough Therapy<\/strong> (CDE) provides expedited review pathways, extended market exclusivity, and enhanced commercial positioning.<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-implications-for-ai-drug-discovery\" class=\"wp-block-heading\">Strategic Implications for AI Drug Discovery<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Validation Milestone<\/strong>: Successful Phase 3 initiation represents a critical validation point for <strong>AI-native drug discovery companies<\/strong>, demonstrating the ability to generate clinically viable candidates with novel mechanisms.<\/li>\n\n\n\n<li><strong>Platform De-risking<\/strong>: Positive Phase 3 data would significantly de-risk Insilico&#8217;s entire Pharma.AI platform, potentially accelerating partnerships and pipeline advancement across multiple therapeutic areas.<\/li>\n\n\n\n<li><strong>Investor Confidence<\/strong>: The milestone reinforces the investment case for AI-driven biotechnology, with implications for the broader computational drug discovery ecosystem.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking information regarding clinical development, regulatory designations, and market opportunities. Actual results may differ due to clinical trial outcomes, regulatory decisions, competitive developments, and market conditions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Insilico Medicine (HKG: 3696) announced the initiation of a Phase 3 clinical trial (CTR20262475, NCT07687459)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":69599,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[99,62,4514,164],"class_list":["post-69598","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-ai","tag-clinical-trial-approval-initiation","tag-hkg-3696","tag-insilico-medicine"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.0) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Insilico Medicine Launches Phase 3 Trial for AI-Discovered Rentosertib in Idiopathic Pulmonary Fibrosis - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Insilico Medicine (HKG: 3696) announced the initiation of a Phase 3 clinical trial (CTR20262475, NCT07687459) for Rentosertib (ISM001-055), a potential first-in-class small-molecule inhibitor for idiopathic pulmonary fibrosis (IPF) discovered using the company&#039;s proprietary generative AI platform, Pharma.AI. The molecule has received Orphan Drug Designation from the U.S. FDA and Breakthrough Therapy Designation from China&#039;s CDE.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=69598\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Insilico Medicine Launches Phase 3 Trial for AI-Discovered Rentosertib in Idiopathic Pulmonary Fibrosis\" \/>\n<meta property=\"og:description\" content=\"Insilico Medicine (HKG: 3696) announced the initiation of a Phase 3 clinical trial (CTR20262475, NCT07687459) for Rentosertib (ISM001-055), a potential first-in-class small-molecule inhibitor for idiopathic pulmonary fibrosis (IPF) discovered using the company&#039;s proprietary generative AI platform, Pharma.AI. The molecule has received Orphan Drug Designation from the U.S. FDA and Breakthrough Therapy Designation from China&#039;s CDE.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=69598\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-08T06:20:08+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-08T06:20:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0804.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69598#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69598\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Insilico Medicine Launches Phase 3 Trial for AI-Discovered Rentosertib in Idiopathic Pulmonary Fibrosis\",\"datePublished\":\"2026-07-08T06:20:08+00:00\",\"dateModified\":\"2026-07-08T06:20:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69598\"},\"wordCount\":477,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69598#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/0804.webp\",\"keywords\":[\"AI\",\"Clinical trial approval \\\/ initiation\",\"HKG: 3696\",\"Insilico Medicine\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69598#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69598\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=69598\",\"name\":\"Insilico Medicine Launches Phase 3 Trial for AI-Discovered Rentosertib in Idiopathic Pulmonary Fibrosis - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69598#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69598#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/0804.webp\",\"datePublished\":\"2026-07-08T06:20:08+00:00\",\"dateModified\":\"2026-07-08T06:20:09+00:00\",\"description\":\"Insilico Medicine (HKG: 3696) announced the initiation of a Phase 3 clinical trial (CTR20262475, NCT07687459) for Rentosertib (ISM001-055), a potential first-in-class small-molecule inhibitor for idiopathic pulmonary fibrosis (IPF) discovered using the company's proprietary generative AI platform, Pharma.AI. The molecule has received Orphan Drug Designation from the U.S. FDA and Breakthrough Therapy Designation from China's CDE.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69598#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69598\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69598#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/0804.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/0804.webp\",\"width\":1080,\"height\":608,\"caption\":\"Insilico Medicine Launches Phase 3 Trial for AI-Discovered Rentosertib in Idiopathic Pulmonary Fibrosis\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69598#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Insilico Medicine Launches Phase 3 Trial for AI-Discovered Rentosertib in Idiopathic Pulmonary Fibrosis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Insilico Medicine Launches Phase 3 Trial for AI-Discovered Rentosertib in Idiopathic Pulmonary Fibrosis - Insight, China&#039;s Pharmaceutical Industry","description":"Insilico Medicine (HKG: 3696) announced the initiation of a Phase 3 clinical trial (CTR20262475, NCT07687459) for Rentosertib (ISM001-055), a potential first-in-class small-molecule inhibitor for idiopathic pulmonary fibrosis (IPF) discovered using the company's proprietary generative AI platform, Pharma.AI. The molecule has received Orphan Drug Designation from the U.S. FDA and Breakthrough Therapy Designation from China's CDE.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=69598","og_locale":"en_US","og_type":"article","og_title":"Insilico Medicine Launches Phase 3 Trial for AI-Discovered Rentosertib in Idiopathic Pulmonary Fibrosis","og_description":"Insilico Medicine (HKG: 3696) announced the initiation of a Phase 3 clinical trial (CTR20262475, NCT07687459) for Rentosertib (ISM001-055), a potential first-in-class small-molecule inhibitor for idiopathic pulmonary fibrosis (IPF) discovered using the company's proprietary generative AI platform, Pharma.AI. The molecule has received Orphan Drug Designation from the U.S. FDA and Breakthrough Therapy Designation from China's CDE.","og_url":"https:\/\/flcube.com\/?p=69598","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-08T06:20:08+00:00","article_modified_time":"2026-07-08T06:20:09+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0804.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=69598#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=69598"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Insilico Medicine Launches Phase 3 Trial for AI-Discovered Rentosertib in Idiopathic Pulmonary Fibrosis","datePublished":"2026-07-08T06:20:08+00:00","dateModified":"2026-07-08T06:20:09+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=69598"},"wordCount":477,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=69598#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0804.webp","keywords":["AI","Clinical trial approval \/ initiation","HKG: 3696","Insilico Medicine"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=69598#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=69598","url":"https:\/\/flcube.com\/?p=69598","name":"Insilico Medicine Launches Phase 3 Trial for AI-Discovered Rentosertib in Idiopathic Pulmonary Fibrosis - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=69598#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=69598#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0804.webp","datePublished":"2026-07-08T06:20:08+00:00","dateModified":"2026-07-08T06:20:09+00:00","description":"Insilico Medicine (HKG: 3696) announced the initiation of a Phase 3 clinical trial (CTR20262475, NCT07687459) for Rentosertib (ISM001-055), a potential first-in-class small-molecule inhibitor for idiopathic pulmonary fibrosis (IPF) discovered using the company's proprietary generative AI platform, Pharma.AI. The molecule has received Orphan Drug Designation from the U.S. FDA and Breakthrough Therapy Designation from China's CDE.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=69598#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=69598"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=69598#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0804.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0804.webp","width":1080,"height":608,"caption":"Insilico Medicine Launches Phase 3 Trial for AI-Discovered Rentosertib in Idiopathic Pulmonary Fibrosis"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=69598#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Insilico Medicine Launches Phase 3 Trial for AI-Discovered Rentosertib in Idiopathic Pulmonary Fibrosis"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0804.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69598","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=69598"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69598\/revisions"}],"predecessor-version":[{"id":69600,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69598\/revisions\/69600"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/69599"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=69598"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=69598"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=69598"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}